GlassScriptPhysician profile
Erin Lechner
NPI 1417781634
$1,691.70
in general payments reported to CMS, 2019-2025
23 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $148 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659 · Education: $32.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.16 |
| Education | $32.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $395.52 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $262.73 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $127.87 | 2025 | |
| Amgen INC. | $126.80 | 2024-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $104.09 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $93.46 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $83.31 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $79.64 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $48.34 | 2025 | Nexletol |
| Lundbeck LLC | $40.32 | 2025 | Rexulti |
| Exact Sciences Corporation | $37.81 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $37.24 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $36.34 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.38 | 2025 | Jardiance |
| Azurity Pharmaceuticals, INC. | $32.37 | 2025 | Edarbi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.80 | 2024-2025 | Xifaxan |
| Antares Pharma, INC. | $22.17 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $20.05 | 2025 | |
| Abbott Laboratories | $19.67 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $18.15 | 2025 | Vaxneuvance, Proquad, Capvaxive |
| Sumitomo Pharma America, INC. | $14.72 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $14.17 | 2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $13.75 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Lechner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.